Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decrease of 37.5% from the October 15th total of 1,600 shares. Based on an average daily volume of 3,200 shares, the short-interest ratio is presently 0.3 days.

Tema Oncology ETF Stock Performance

Shares of NASDAQ:CANC opened at $26.20 on Friday. The company’s fifty day moving average is $28.30 and its 200-day moving average is $28.13. Tema Oncology ETF has a 52 week low of $22.57 and a 52 week high of $30.11. The company has a market capitalization of $45.58 million, a PE ratio of 26.86 and a beta of 1.11.

Hedge Funds Weigh In On Tema Oncology ETF

A hedge fund recently bought a new stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new stake in Tema Oncology ETF (NASDAQ:CANC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF as of its most recent filing with the SEC.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.